Drug Sponsors

Horizon and Mallinckrodt to co-promote Duexis

Monday, June 18, 2012 09:54 AM

Mallinckrodt, the pharmaceuticals business of Covidien, has entered into a co-promotion agreement with Horizon Pharma of Deerfield, Ill., to promote the latter’s proprietary drug Duexis, a single-tablet combination of ibuprofen and the histamine H2-receptor antagonist famotidine for symptom relief of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper gastrointestinal ulcers.

More... »

Scripps Research inks 5-year research collaboration with BMS

Friday, June 15, 2012 03:37 PM

The Scripps Research Institute, an independent, not-for-profit organization focused on research in the biomedical sciences, has entered into a five-year collaboration with Bristol-Myers Squibb (BMS) focusing on applying novel chemistry to drug discovery and synthesis.

More... »

HGS sets July 16 deadline for acquisition proposals

Friday, June 15, 2012 02:09 PM

In connection with its ongoing strategic alternative review process, Human Genome Sciences (HGS) has set a bid date of July 16, 2012, for the submission of definitive proposals to acquire all outstanding common shares of HGS.

More... »

Valeant Pharmaceuticals to acquire OraPharma

Friday, June 15, 2012 01:42 PM

Valeant Pharmaceuticals International has agreed to acquire OraPharma, a Horsham, Penn.-based specialty oral health company that develops and commercializes products that improve and maintain oral health, from Water Street Healthcare Partners, a private equity firm focused exclusively on the health care industry. 

More... »

Analytical Solutions expands, changes name to Tergus Pharma

Friday, June 15, 2012 09:31 AM

In response to company growth and expansion of topical pharmaceutical product development services, Analytical Solutions of Research Triangle Park, N.C., has changed its name to Tergus Pharma, to better echo the company's new growth trajectory.

More... »

Lilly expands partnership with Novast for branded generics

Thursday, June 14, 2012 02:53 PM

In support of its commitment to maximize growth opportunities in China, Eli Lilly has increased its network of manufacturing capabilities in this key emerging market country through an expanded collaboration with Novast Laboratories.

More... »

Newron to acquire Swedish neurogenesis company NeuroNova

Thursday, June 14, 2012 02:28 PM

Newron Pharmaceuticals of Italy has signed an agreement with key shareholders for the acquisition of up to 100% of the shares of Stockholm-based privately-owned NeuroNova, in an all-share transaction valuing the company at $19.4 million (closing share price June 11, 2012).

More... »

Upsher-Smith to acquire U.K.-based Proximagen

Thursday, June 14, 2012 12:33 PM

Upsher-Smith Laboratories, a privately-owned specialty pharmaceutical company of Maple Grove, Minn., has agreed to acquire Proximagen Group, a European biotech focused on the development and commercialization of novel therapeutics for diseases of the central nervous system and inflammation. Upsher-Smith intends to retain operations in Cambridge and London, England.

More... »

Rhythm raises $25M in Series B financing for diabetes and obesity

Thursday, June 14, 2012 09:14 AM

Rhythm, a biotech based in Boston, Mass., has raised $25 million in a Series B financing round, bringing the total capital raised to $65 million.

More... »

Blaze Bioscience raises $5M in Series A financing

Monday, June 11, 2012 03:36 PM

Blaze Bioscience, a privately-held Seattle-based biotechnology company dedicated to developing products that assist surgeons in their quest to improve the lives of cancer patients, has raised $5 million in Series A financing.

More... »